+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tropical & Vector-borne Infectious Diseases Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Tropical & Vector-borne Infectious Diseases Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Tropical & Vector-borne Infectious Diseases Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6082177
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The global landscape of tropical and vector-borne infectious diseases presents a complex tapestry of biological threats, socio-environmental drivers, and technological breakthroughs. As urbanization accelerates, climate patterns shift, and international travel rebounds, pathogens such as dengue, malaria, chikungunya, yellow fever, and Zika virus have resurged with renewed intensity, imposing significant burdens on public health systems and economies. This executive summary synthesizes critical insights from the latest market research, highlighting transformative shifts, regulatory headwinds, and emerging opportunities. Through an examination of diagnostic innovations, treatment advances, regional dynamics, and stakeholder ecosystems, this analysis equips decision-makers with a comprehensive understanding of current trends, challenges, and strategic levers. Drawing on robust segmentation frameworks and authoritative data, the findings herein illuminate pathways to optimize resource allocation, accelerate R&D, and strengthen prevention strategies. Ultimately, this introduction lays the foundation for a targeted exploration of how industry leaders can harness scientific progress and policy developments to mitigate disease impact and drive sustainable growth in an evolving global context.

Transformative Shifts in the Infectious Diseases Landscape

The past decade has witnessed profound shifts reshaping how public health authorities, healthcare providers, and industry stakeholders engage with tropical and vector-borne diseases. Advances in molecular diagnostics have accelerated pathogen detection, with loop-mediated isothermal amplification and polymerase chain reaction assays delivering unprecedented specificity and turnaround times. At the same time, digital health applications and point-of-care testing have extended diagnostic reach into remote and underserved communities, bridging critical gaps in early case identification. Concurrently, the emergence of next-generation antimalarials and novel antivirals underscores a pharmaceutical renaissance, driven by strategic collaborations between biotech firms, academic institutions, and international health organizations.

On the prevention front, vector control measures such as indoor residual spraying and insecticide-treated nets are being augmented by innovative personal protective solutions and emerging vaccine platforms. Dengue vaccine uptake is gaining traction, while live attenuated and subunit vaccines for yellow fever and Zika virus are advancing through late-stage clinical trials. Policy landscapes have also evolved; public health departments are adopting integrated surveillance systems that leverage real-time data analytics, enhancing outbreak prediction and response capabilities. Together, these transformative shifts are redefining the paradigm for combating vector-borne threats, setting the stage for more resilient, data-driven public health strategies.

Cumulative Impact of U.S. Tariffs on Disease Control Efforts

In 2025, the shifting tariffs imposed by the United States on medical imports have had a cascading impact across the tropical disease supply chain. Increased duties on diagnostic reagents-particularly rapid diagnostic tests relying on antibody and antigen detection-have elevated procurement costs for laboratories and hospitals, prompting some healthcare providers to negotiate long-term contracts or explore alternative suppliers. Similarly, tariffs on components used in molecular diagnostics, such as reagents for isothermal amplification and polymerase chain reaction, have driven up unit prices, affecting both centralized laboratories and emerging point-of-care platforms.

Pharmaceutical supply chains have not been immune. Duties on active pharmaceutical ingredients for artemisinin-based therapies and antiviral compounds have squeezed manufacturer margins, encouraging strategic stockpiling and vertical integration efforts by drug producers. Meanwhile, supportive care essentials, including intravenous fluids and analgesics, have seen moderate price adjustments, exerting pressure on hospital budgets in regions heavily reliant on imports. Regulatory responses have varied: some public health departments have accelerated approvals for locally manufactured alternatives, while international health organizations are negotiating tariff exemptions for critical public health commodities. These cumulative effects underscore the need for agility in procurement strategies and collaborative policy advocacy to ensure uninterrupted access to essential diagnostics and therapeutics.

Key Segmentation Insights Across the Value Chain

Insight into market segmentation reveals nuanced dynamics across disease categories, diagnostic modalities, treatment approaches, prevention strategies, research initiatives, and stakeholder groups. Within disease type, acute and chronic presentations of chikungunya and dengue fever demand distinct diagnostic and therapeutic pathways, while the dual Plasmodium species driving malaria necessitate tailored drug regimens. Mild and severe yellow fever cases, alongside asymptomatic and symptomatic Zika virus infections, further complicate clinical decision-making and resource allocation. Diagnostic methods range from clinical judgment and symptom assessment to advanced serological assays like ELISA and immunofluorescence, with rapid tests offering antibody or antigen detection at the point of care. Molecular analytics harness LAMP and PCR to deliver rapid, high-fidelity results, shifting the balance toward earlier intervention.

Treatment and medication segmentation highlights the prominence of artemisinin-based therapies and chloroquine for malaria, the expanding role of oseltamivir and ribavirin in antiviral protocols, and the critical importance of fluid replacement and pain management in supportive care. Prevention strategies integrate personal protective measures-such as insect repellents and protective clothing-with vaccination campaigns for dengue and yellow fever and comprehensive vector control programs employing indoor residual spraying and insecticide-treated nets. Research and development efforts, spanning digital health applications and point-of-care innovations to next-generation antimalarials, novel antivirals, live attenuated vaccines, and subunit vaccine candidates, reflect a vibrant innovation ecosystem. Finally, stakeholder segmentation underscores the collaborative interplay among international health organizations, public health departments, hospitals, primary care clinics, biotech firms, drug manufacturers, private sector labs, and universities driving market evolution.

Key Regional Insights Shaping Market Dynamics

Regional dynamics continue to influence disease burden and market priorities. In the Americas, resurgence of dengue and chikungunya has intensified demand for rapid diagnostic tests and expanded vaccination programs, with local manufacturers scaling up to meet domestic and export requirements. Collaborative initiatives between public health departments and research institutes have accelerated field trials of vector control innovations, particularly in urban centers.

Europe, the Middle East, and Africa present a heterogeneous landscape: North African nations and parts of the Middle East face sporadic yellow fever outbreaks, prompting investments in cold-chain infrastructure for vaccine deployment. Sub-Saharan Africa remains the epicenter of malaria, driving sustained demand for artemisinin-based therapies and exploring novel insecticide-treated net technologies. Meanwhile, research partnerships between European biotech firms and African universities are spearheading next-generation antiviral and vaccine candidates.

In the Asia-Pacific, rapid urbanization and ecological changes have expanded Aedes mosquito habitats, elevating the risk of dengue and Zika transmission. Governments are prioritizing integrated surveillance systems, combining clinical evaluation data with molecular diagnostics to optimize resource allocation. Regional pharmaceutical companies are also forging alliances to advance cost-effective drug development and distribution networks across island nations and continental markets.

Key Company Insights Driving Innovation and Access

Corporate activity reveals strategic positioning by industry leaders across diagnostics, therapeutics, and prevention. Abbott Laboratories and Bio-Rad Laboratories have fortified their portfolios in molecular diagnostics and serological testing, driving innovations in ELISA platforms and PCR-based solutions. Roche’s footprint in rapid diagnostic tests has expanded through targeted acquisitions, while Alere’s antibody and antigen detection assays continue to gain traction in point-of-care settings.

Pharmaceutical giants such as GlaxoSmithKline and Sanofi have advanced dengue and yellow fever vaccine programs, leveraging live attenuated and subunit vaccine technologies. Merck & Co. and Johnson & Johnson are collaborating on next-generation antiviral candidates, while Novavax and Themis Bioscience GmbH are accelerating clinical development of novel vaccine constructs. In emerging markets, Bharat Biotech and Indian Immunologicals Limited are scaling production of vector-borne disease vaccines, supported by research partnerships with the Institute Pasteur. Meanwhile, Mylan and Takeda are optimizing global distribution channels for antimalarials and supportive care therapies, underscoring the importance of supply chain resilience.

Actionable Recommendations for Industry Leaders

Industry leaders can capitalize on emerging opportunities by adopting a three-pronged strategy: first, invest in integrated diagnostic platforms that combine molecular, serological, and digital health modalities to enhance surveillance and case management. Prioritize partnerships with biotech firms and academic centers to co-develop rapid, cost-effective assays that can be deployed across diverse care settings. Second, strengthen supply chain resilience by diversifying manufacturing bases, negotiating long-term procurement agreements, and advocating for tariff exemptions on essential reagents and APIs. This will safeguard against geopolitical disruptions and ensure stable access to critical diagnostics and therapeutics.

Third, foster cross-sector collaborations to accelerate vaccine and drug development. Engage with public health departments, international health organizations, and research institutes to leverage shared data, streamline clinical trial processes, and secure funding support. Emphasize adaptive clinical trial designs that allow real-time data integration, enabling more responsive regulatory pathways. Finally, embed digital tools and IoT-enabled vector control solutions into community health programs to monitor outbreak hotspots dynamically, optimize resource deployment, and measure intervention efficacy. By executing these actionable recommendations, leaders can drive sustainable growth while reducing disease burden.

Conclusion: Seizing the Next Frontier in Disease Control

The intersection of evolving pathogen dynamics, technological breakthroughs, and policy shifts presents both challenges and opportunities for the tropical and vector-borne disease sector. Robust segmentation analysis provides clarity on where demand is concentrated, while regional and corporate insights illuminate strategic corridors for investment and collaboration. As diagnostic capabilities become more decentralized and vaccines enter later-stage trials, the industry stands at a pivotal moment: stakeholders who proactively align R&D efforts with market needs, reinforce supply chain resilience, and champion integrated prevention strategies will shape the next frontier of disease control. Anchored by data-driven decision-making and agile partnerships, this momentum can translate into improved health outcomes, economic stability, and long-term resilience against emerging threats.

Market Segmentation & Coverage

This research report categorizes the Tropical & Vector-borne Infectious Diseases Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Chikungunya
    • Acute Infections
    • Chronic Infections
  • Dengue Fever
    • Acute Cases
    • Chronic Cases
  • Malaria
    • Plasmodium Falciparum
    • Plasmodium Vivax
  • Yellow Fever
    • Mild Cases
    • Severe Cases
  • Zika Virus
    • Asymptomatic Infections
    • Symptomatic Infections
  • Clinical Evaluation
    • Clinical Judgement
    • Symptom Assessment
  • Molecular Diagnostics
    • Loop-Mediated Isothermal Amplification (LAMP)
    • Polymerase Chain Reaction
  • Rapid Diagnostic Tests (RDTs)
    • Antibody Detection
    • Antigen Detection
  • Serological Tests
    • ELISA
    • Immunofluorescence Assays
  • Antimalarial Drugs
    • Artemisinin-based Therapies
    • Chloroquine
  • Antiviral Drugs
    • Oseltamivir
    • Ribavirin
  • Supportive Care
    • Fluid Replacement
    • Pain Management
  • Personal Protective Measures
    • Insect Repellents
    • Protective Clothing
  • Vaccination
    • Dengue Vaccine (Dengvaxia)
    • Yellow Fever Vaccine
  • Vector Control Measures
    • Indoor Residual Spraying
    • Insecticide-Treated Nets
  • Diagnostic Innovations
    • Digital Health Applications
    • Point-of-Care Testing
  • Drug Development
    • Next-Generation Antimalarials
    • Novel Antivirals
  • Vaccine Research
    • Live Attenuated Vaccines
    • Subunit Vaccines
  • Governments And NGOs
    • International Health Organizations
    • Public Health Departments
  • Healthcare Providers
    • Hospitals
    • Primary Care Clinics
  • Pharmaceutical Companies
    • Biotech Firms
    • Drug Manufacturers
  • Research Institutes
    • Private Sector Labs
    • Universities

This research report categorizes the Tropical & Vector-borne Infectious Diseases Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Tropical & Vector-borne Infectious Diseases Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Alere, Inc.
  • Bharat Biotech
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Indian Immunologicals Limited
  • Institute of Pasteur
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novavax, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Themis Bioscience GmbH

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tropical & Vector-borne Infectious Diseases Market, by Disease Type
8.1. Introduction
8.2. Chikungunya
8.2.1. Acute Infections
8.2.2. Chronic Infections
8.3. Dengue Fever
8.3.1. Acute Cases
8.3.2. Chronic Cases
8.4. Malaria
8.4.1. Plasmodium Falciparum
8.4.2. Plasmodium Vivax
8.5. Yellow Fever
8.5.1. Mild Cases
8.5.2. Severe Cases
8.6. Zika Virus
8.6.1. Asymptomatic Infections
8.6.2. Symptomatic Infections
9. Tropical & Vector-borne Infectious Diseases Market, by Diagnostic Methods
9.1. Introduction
9.2. Clinical Evaluation
9.2.1. Clinical Judgement
9.2.2. Symptom Assessment
9.3. Molecular Diagnostics
9.3.1. Loop-Mediated Isothermal Amplification (LAMP)
9.3.2. Polymerase Chain Reaction
9.4. Rapid Diagnostic Tests (RDTs)
9.4.1. Antibody Detection
9.4.2. Antigen Detection
9.5. Serological Tests
9.5.1. ELISA
9.5.2. Immunofluorescence Assays
10. Tropical & Vector-borne Infectious Diseases Market, by Treatment And Medication
10.1. Introduction
10.2. Antimalarial Drugs
10.2.1. Artemisinin-based Therapies
10.2.2. Chloroquine
10.3. Antiviral Drugs
10.3.1. Oseltamivir
10.3.2. Ribavirin
10.4. Supportive Care
10.4.1. Fluid Replacement
10.4.2. Pain Management
11. Tropical & Vector-borne Infectious Diseases Market, by Prevention Strategies
11.1. Introduction
11.2. Personal Protective Measures
11.2.1. Insect Repellents
11.2.2. Protective Clothing
11.3. Vaccination
11.3.1. Dengue Vaccine (Dengvaxia)
11.3.2. Yellow Fever Vaccine
11.4. Vector Control Measures
11.4.1. Indoor Residual Spraying
11.4.2. Insecticide-Treated Nets
12. Tropical & Vector-borne Infectious Diseases Market, by Research And Development
12.1. Introduction
12.2. Diagnostic Innovations
12.2.1. Digital Health Applications
12.2.2. Point-of-Care Testing
12.3. Drug Development
12.3.1. Next-Generation Antimalarials
12.3.2. Novel Antivirals
12.4. Vaccine Research
12.4.1. Live Attenuated Vaccines
12.4.2. Subunit Vaccines
13. Tropical & Vector-borne Infectious Diseases Market, by Stakeholder Types
13.1. Introduction
13.2. Governments And NGOs
13.2.1. International Health Organizations
13.2.2. Public Health Departments
13.3. Healthcare Providers
13.3.1. Hospitals
13.3.2. Primary Care Clinics
13.4. Pharmaceutical Companies
13.4.1. Biotech Firms
13.4.2. Drug Manufacturers
13.5. Research Institutes
13.5.1. Private Sector Labs
13.5.2. Universities
14. Americas Tropical & Vector-borne Infectious Diseases Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Tropical & Vector-borne Infectious Diseases Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Tropical & Vector-borne Infectious Diseases Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbott Laboratories
17.3.2. Alere, Inc.
17.3.3. Bharat Biotech
17.3.4. Bio-Rad Laboratories, Inc.
17.3.5. F. Hoffmann-La Roche AG
17.3.6. GlaxoSmithKline plc
17.3.7. Indian Immunologicals Limited
17.3.8. Institute of Pasteur
17.3.9. Johnson & Johnson
17.3.10. Merck & Co., Inc.
17.3.11. Mylan N.V.
17.3.12. Novavax, Inc.
17.3.13. Sanofi S.A.
17.3.14. Takeda Pharmaceutical Company Limited
17.3.15. Themis Bioscience GmbH
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET MULTI-CURRENCY
FIGURE 2. TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET MULTI-LANGUAGE
FIGURE 3. TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHODS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHODS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY TREATMENT AND MEDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY TREATMENT AND MEDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PREVENTION STRATEGIES, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PREVENTION STRATEGIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STAKEHOLDER TYPES, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STAKEHOLDER TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHIKUNGUNYA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ACUTE INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHRONIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHIKUNGUNYA, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DENGUE FEVER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ACUTE CASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHRONIC CASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DENGUE FEVER, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MALARIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PLASMODIUM FALCIPARUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PLASMODIUM VIVAX, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MALARIA, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MILD CASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SEVERE CASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY YELLOW FEVER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ZIKA VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ASYMPTOMATIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SYMPTOMATIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ZIKA VIRUS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CLINICAL EVALUATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CLINICAL JUDGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SYMPTOM ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CLINICAL EVALUATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP), BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIBODY DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY TREATMENT AND MEDICATION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIMALARIAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ARTEMISININ-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RIBAVIRIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY FLUID REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PREVENTION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PERSONAL PROTECTIVE MEASURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY INSECT REPELLENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PROTECTIVE CLOTHING, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PERSONAL PROTECTIVE MEASURES, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DENGUE VACCINE (DENGVAXIA), BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY YELLOW FEVER VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINATION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VECTOR CONTROL MEASURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY INDOOR RESIDUAL SPRAYING, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY INSECTICIDE-TREATED NETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VECTOR CONTROL MEASURES, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC INNOVATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIGITAL HEALTH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY NEXT-GENERATION ANTIMALARIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY NOVEL ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINE RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINE RESEARCH, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STAKEHOLDER TYPES, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY GOVERNMENTS AND NGOS, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY INTERNATIONAL HEALTH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY GOVERNMENTS AND NGOS, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY BIOTECH FIRMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DRUG MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PRIVATE SECTOR LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 98. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 99. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHIKUNGUNYA, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DENGUE FEVER, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MALARIA, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY YELLOW FEVER, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ZIKA VIRUS, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CLINICAL EVALUATION, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2030 (USD MILLION)
TABLE 110. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY TREATMENT AND MEDICATION, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PREVENTION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PERSONAL PROTECTIVE MEASURES, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINATION, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VECTOR CONTROL MEASURES, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINE RESEARCH, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STAKEHOLDER TYPES, 2018-2030 (USD MILLION)
TABLE 124. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY GOVERNMENTS AND NGOS, 2018-2030 (USD MILLION)
TABLE 125. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 126. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 127. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 128. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHIKUNGUNYA, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DENGUE FEVER, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MALARIA, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY YELLOW FEVER, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ZIKA VIRUS, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CLINICAL EVALUATION, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY TREATMENT AND MEDICATION, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PREVENTION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PERSONAL PROTECTIVE MEASURES, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINATION, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VECTOR CONTROL MEASURES, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINE RESEARCH, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STAKEHOLDER TYPES, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY GOVERNMENTS AND NGOS, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHIKUNGUNYA, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DENGUE FEVER, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MALARIA, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY YELLOW FEVER, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ZIKA VIRUS, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CLINICAL EVALUATION, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2030 (USD MILLION)
TABLE 167. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY TREATMENT AND MEDICATION, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PREVENTION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PERSONAL PROTECTIVE MEASURES, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINATION, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VECTOR CONTROL MEASURES, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINE RESEARCH, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STAKEHOLDER TYPES, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY GOVERNMENTS AND NGOS, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 185. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 186. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHIKUNGUNYA, 2018-2030 (USD MILLION)
TABLE 187. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DENGUE FEVER, 2018-2030 (USD MILLION)
TABLE 188. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MALARIA, 2018-2030 (USD MILLION)
TABLE 189. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY YELLOW FEVER, 2018-2030 (USD MILLION)
TABLE 190. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ZIKA VIRUS, 2018-2030 (USD MILLION)
TABLE 191. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
TABLE 192. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CLINICAL EVALUATION, 2018-2030 (USD MILLION)
TABLE 193. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 194. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2030 (USD MILLION)
TABLE 195. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 196. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY TREATMENT AND MEDICATION, 2018-2030 (USD MILLION)
TABLE 197. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 198. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 199. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 200. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PREVENTION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 201. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PERSONAL PROTECTIVE MEASURES, 2018-2030 (USD MILLION)
TABLE 202. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINATION, 2018-2030 (USD MILLION)
TABLE 203. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VECTOR CONTROL MEASURES, 2018-2030 (USD MILLION)
TABLE 204. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 205. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 206. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 207. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINE RESEARCH, 2018-2030 (USD MILLION)
TABLE 208. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STAKEHOLDER TYPES, 2018-2030 (USD MILLION)
TABLE 209. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY GOVERNMENTS AND NGOS, 2018-2030 (USD MILLION)
TABLE 210. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 211. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 212. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 213. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 214. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHIKUNGUNYA, 2018-2030 (USD MILLION)
TABLE 215. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DENGUE FEVER, 2018-2030 (USD MILLION)
TABLE 216. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MALARIA, 2018-2030 (USD MILLION)
TABLE 217. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY YELLOW FEVER, 2018-2030 (USD MILLION)
TABLE 218. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ZIKA VIRUS, 2018-2030 (USD MILLION)
TABLE 219. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
TABLE 220. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CLINICAL EVALUATION, 2018-2030 (USD MILLION)
TABLE 221. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 222. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2030 (USD MILLION)
TABLE 223. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 224. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY TREATMENT AND MEDICATION, 2018-2030 (USD MILLION)
TABLE 225. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 226. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 227. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 228. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PREVENTION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 229. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PERSONAL PROTECTIVE MEASURES, 2018-2030 (USD MILLION)
TABLE 230. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINATION, 2018-2030 (USD MILLION)
TABLE 231. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VECTOR CONTROL MEASURES, 2018-2030 (USD MILLION)
TABLE 232. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 233. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 234. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 235. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINE RESEARCH, 2018-2030 (USD MILLION)
TABLE 236. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STAKEHOLDER TYPES, 2018-2030 (USD MILLION)
TABLE 237. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY GOVERNMENTS AND NGOS, 2018-2030 (USD MILLION)
TABLE 238. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 239. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 240. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 241. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 242. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHIKUNGUNYA, 2018-2030 (USD MILLION)
TABLE 243. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DENGUE FEVER, 2018-2030 (USD MILLION)
TABLE 244. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MALARIA, 2018-2030 (USD MILLION)
TABLE 245. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY YELLOW FEVER, 2018-2030 (USD MILLION)
TABLE 246. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ZIKA VIRUS, 2018-2030 (USD MILLION)
TABLE 247. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
TABLE 248. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CLINICAL EVALUATION, 2018-2030 (USD MILLION)
TABLE 249. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 250. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS), 2018-2030 (USD MILLION)
TABLE 251. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 252. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY TREATMENT AND MEDICATION, 2018-2030 (USD MILLION)
TABLE 253. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 254. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2030 (USD MILLION)
TABLE 255. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 256. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PREVENTION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 257. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PERSONAL PROTECTIVE MEASURES, 2018-2030 (USD MILLION)
TABLE 258. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINATION, 2018-2030 (USD MILLION)
TABLE 259. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VECTOR CONTROL MEASURES, 2018-2030 (USD MILLION)
TABLE 260. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 261. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 262. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 263. UNITED STATES TROPICAL & VECTO

Companies Mentioned

  • Abbott Laboratories
  • Alere, Inc.
  • Bharat Biotech
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Indian Immunologicals Limited
  • Institute of Pasteur
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novavax, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Themis Bioscience GmbH

Methodology

Loading
LOADING...

Related Topics

Related Reports

Mosquitoes, Communities, and Public Health in Texas - Product Image

Mosquitoes, Communities, and Public Health in Texas

  • Book
  • United States
Chikungunya and Zika Viruses. Global Emerging Health Threats - Product Image

Chikungunya and Zika Viruses. Global Emerging Health Threats

  • Book
  • Global
United States Natural Insect Repellent Market, By Region, Competition, Forecast & Opportunities, 2020-2030F - Product Image

United States Natural Insect Repellent Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

  • Report
  • 81 Pages
  • United States
From
North America Mosquito Repellent Market, By Country, Competition, Forecast & Opportunities, 2020-2030F - Product Image

North America Mosquito Repellent Market, By Country, Competition, Forecast & Opportunities, 2020-2030F

  • Report
  • 131 Pages
  • North America
From
Mosquito Borne Diseases Market Report 2025 - Product Image

Mosquito Borne Diseases Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.